Rafferty Asset Management’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $850K | Sell |
92,144
-35,310
| -28% | -$326K | ﹤0.01% | 791 |
|
|
2025
Q1 | $1.09M | Buy |
127,454
+52,853
| +71% | +$453K | ﹤0.01% | 725 |
|
|
2024
Q4 | $801K | Sell |
74,601
-64,985
| -47% | -$698K | ﹤0.01% | 829 |
|
|
2024
Q3 | $793K | Sell |
139,586
-84,728
| -38% | -$481K | ﹤0.01% | 845 |
|
|
2024
Q2 | $947K | Sell |
224,314
-445,631
| -67% | -$1.88M | ﹤0.01% | 833 |
|
|
2024
Q1 | $3.41M | Buy |
669,945
+437,914
| +189% | +$2.23M | 0.01% | 546 |
|
|
2023
Q4 | $2.16M | Sell |
232,031
-38,757
| -14% | -$361K | 0.01% | 656 |
|
|
2023
Q3 | $1.77M | Sell |
270,788
-79,874
| -23% | -$523K | 0.01% | 647 |
|
|
2023
Q2 | $2.85M | Sell |
350,662
-114,593
| -25% | -$932K | 0.02% | 545 |
|
|
2023
Q1 | $3.99M | Buy |
465,255
+501
| +0.1% | +$4.29K | 0.03% | 433 |
|
|
2022
Q4 | $4.3M | Buy |
464,754
+189,808
| +69% | +$1.76M | 0.04% | 411 |
|
|
2022
Q3 | $2.84M | Buy |
274,946
+107,130
| +64% | +$1.11M | 0.03% | 431 |
|
|
2022
Q2 | $1.68M | Sell |
167,816
-200,283
| -54% | -$2.01M | 0.02% | 516 |
|
|
2022
Q1 | $4.53M | Buy |
368,099
+125,185
| +52% | +$1.54M | 0.03% | 412 |
|
|
2021
Q4 | $4.21M | Buy |
242,914
+76,282
| +46% | +$1.32M | 0.02% | 451 |
|
|
2021
Q3 | $2.99M | Sell |
166,632
-1,657
| -1% | -$29.7K | 0.02% | 479 |
|
|
2021
Q2 | $3.85M | Buy |
168,289
+49,312
| +41% | +$1.13M | 0.02% | 414 |
|
|
2021
Q1 | $1.78M | Buy |
+118,977
| New | +$1.78M | 0.01% | 655 |
|